AR013384A1 - Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4 - Google Patents
Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4Info
- Publication number
- AR013384A1 AR013384A1 ARP980103778A ARP980103778A AR013384A1 AR 013384 A1 AR013384 A1 AR 013384A1 AR P980103778 A ARP980103778 A AR P980103778A AR P980103778 A ARP980103778 A AR P980103778A AR 013384 A1 AR013384 A1 AR 013384A1
- Authority
- AR
- Argentina
- Prior art keywords
- vla
- compounds
- intermediated
- leukocyte adhesion
- compounds inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen compuestos que se adhieren a VLA-4. Algunos de estos compuestos inhiben también la adhesion a los leucocitos y en particular, laadhesion a los leucocitos intermediada por VLA-4. Dichos compuestos son utiles en el tratamiento de enfermedades inflamatorias de un paciente mamífero, porejemplo en un ser humano tal como asma, enfermedad de Alzheimer,aterosclerosis, demencia causada por SIDA, diabetes, enfermedades inflamatorias del intestino,artritis reumatoide, transplante detejidos, metástasis de tumores, e isquemia de miocardio. Los compuestos pueden ser administrados también para eltratamiento de enfermedades inflamatorias cerebrales tales como esclerois multiple.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92039497A | 1997-07-31 | 1997-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR013384A1 true AR013384A1 (es) | 2000-12-27 |
Family
ID=25443662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980103778A AR013384A1 (es) | 1997-07-31 | 1998-07-30 | Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1001972A1 (es) |
JP (1) | JP2001512134A (es) |
KR (1) | KR20010022411A (es) |
CN (1) | CN1133648C (es) |
AR (1) | AR013384A1 (es) |
AU (1) | AU756696B2 (es) |
BR (1) | BR9812114A (es) |
CA (1) | CA2290747A1 (es) |
HU (1) | HUP0004259A3 (es) |
IL (1) | IL133640A0 (es) |
NO (1) | NO20000450L (es) |
NZ (1) | NZ502582A (es) |
PL (1) | PL338423A1 (es) |
TW (1) | TW534910B (es) |
WO (1) | WO1999006431A1 (es) |
ZA (1) | ZA986827B (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291511B1 (en) | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
AU7667498A (en) * | 1997-05-30 | 1998-12-30 | Celltech Therapeutics Limited | Anti-inflammatory tyrosine derivatives |
ATE249421T1 (de) | 1997-06-23 | 2003-09-15 | Tanabe Seiyaku Co | Inhibitoren der alpha4-beta1 vermittelten zelladhäsion |
US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
AU3260399A (en) | 1998-02-26 | 1999-09-15 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
US7396526B1 (en) | 1998-11-12 | 2008-07-08 | Johnson & Johnson Consumer Companies, Inc. | Skin care composition |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002535316A (ja) | 1999-01-22 | 2002-10-22 | エラン ファーマシューティカルズ,インコーポレイテッド | Vla−4により媒介される白血球接着を阻害する縮合環へテロアリールおよび複素環式化合物 |
CA2359115C (en) | 1999-01-22 | 2011-06-21 | Elan Pharmaceuticals, Inc. | Acyl derivatives which treat vla-4 related disorders |
CA2359114A1 (en) * | 1999-01-25 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
BR0013248A (pt) * | 1999-08-13 | 2002-07-23 | Biogen Inc | Inibidores da adesão celular |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
NZ518886A (en) | 1999-12-28 | 2004-02-27 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
EP1332132B1 (en) | 2000-04-17 | 2007-10-10 | UCB Pharma, S.A. | Enamine derivatives as cell adhesion molecules |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6740654B2 (en) | 2000-07-07 | 2004-05-25 | Celltech R & D Limited | Squaric acid derivatives |
EP1305291A1 (en) | 2000-08-02 | 2003-05-02 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
YU12203A (sh) | 2000-08-18 | 2006-03-03 | Ajinomoto Co.Inc. | Novi derivati fenilalanina |
MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
US6607735B2 (en) | 2000-12-21 | 2003-08-19 | Johnson & Johnson Consumer Companies, Inc. | Method for reducing the appearance of dark circles under the eyes |
JP2004526733A (ja) * | 2001-03-20 | 2004-09-02 | メルク エンド カムパニー インコーポレーテッド | 強力な細胞接着阻害剤としての置換n−アリールスルホニル−プロリン誘導体 |
DE10127126A1 (de) * | 2001-06-05 | 2002-12-19 | Forschungszentrum Juelich Gmbh | Geschützte Tyrosinderivate, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung von O-(2-[·18·F]-Fluorethyl)-L-tyrosin |
MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
EP1592387A4 (en) * | 2003-01-24 | 2009-05-06 | Elan Pharm Inc | COMPOSITION AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS |
CA2528723A1 (en) * | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
KR20110098980A (ko) | 2003-12-22 | 2011-09-02 | 아지노모토 가부시키가이샤 | 신규한 페닐알라닌 유도체 |
CA2714335A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
KR20110008086A (ko) | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
JP2012503595A (ja) * | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
KR20170052526A (ko) | 2014-03-13 | 2017-05-12 | 프로테나 바이오사이언시즈 리미티드 | 다발성 경화증에 대한 병용 치료 |
EP3873900A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737898B (en) * | 1972-11-24 | 1974-07-31 | Hoffmann La Roche | Peptides |
CA1102316A (en) * | 1975-12-09 | 1981-06-02 | Shosuke Okamoto | N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof |
AU1354292A (en) * | 1991-03-18 | 1992-10-21 | Pentapharm Ag | Parasubstituted phenylalanine derivates |
AU693143B2 (en) * | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
-
1998
- 1998-07-30 CA CA002290747A patent/CA2290747A1/en not_active Abandoned
- 1998-07-30 HU HU0004259A patent/HUP0004259A3/hu unknown
- 1998-07-30 KR KR1020007000991A patent/KR20010022411A/ko not_active Application Discontinuation
- 1998-07-30 AU AU86611/98A patent/AU756696B2/en not_active Ceased
- 1998-07-30 WO PCT/US1998/015313 patent/WO1999006431A1/en not_active Application Discontinuation
- 1998-07-30 AR ARP980103778A patent/AR013384A1/es unknown
- 1998-07-30 CN CNB988077531A patent/CN1133648C/zh not_active Expired - Fee Related
- 1998-07-30 NZ NZ502582A patent/NZ502582A/en unknown
- 1998-07-30 PL PL98338423A patent/PL338423A1/xx not_active IP Right Cessation
- 1998-07-30 IL IL13364098A patent/IL133640A0/xx unknown
- 1998-07-30 ZA ZA9806827A patent/ZA986827B/xx unknown
- 1998-07-30 JP JP2000505186A patent/JP2001512134A/ja not_active Withdrawn
- 1998-07-30 EP EP98937990A patent/EP1001972A1/en not_active Withdrawn
- 1998-07-30 BR BR9812114-6A patent/BR9812114A/pt not_active Application Discontinuation
- 1998-07-31 TW TW087112638A patent/TW534910B/zh not_active IP Right Cessation
-
2000
- 2000-01-28 NO NO20000450A patent/NO20000450L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20000450L (no) | 2000-03-28 |
JP2001512134A (ja) | 2001-08-21 |
NZ502582A (en) | 2002-07-26 |
CN1265668A (zh) | 2000-09-06 |
BR9812114A (pt) | 2000-07-18 |
CA2290747A1 (en) | 1999-02-11 |
CN1133648C (zh) | 2004-01-07 |
AU756696B2 (en) | 2003-01-23 |
KR20010022411A (ko) | 2001-03-15 |
HUP0004259A3 (en) | 2001-05-28 |
EP1001972A1 (en) | 2000-05-24 |
HUP0004259A2 (hu) | 2001-04-28 |
ZA986827B (en) | 2000-05-02 |
PL338423A1 (en) | 2000-11-06 |
IL133640A0 (en) | 2001-04-30 |
AU8661198A (en) | 1999-02-22 |
TW534910B (en) | 2003-06-01 |
WO1999006431A1 (en) | 1999-02-11 |
NO20000450D0 (no) | 2000-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR013384A1 (es) | Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4 | |
ES2221183T3 (es) | Compuestos oxicarbamilo que inhiben la adhesion de leucocitos mediada por vla-4. | |
BR9812118A (pt) | Compostos do tipo 4-amino-fenilalanina que inibem adesão de leucócito mediada por vla-4 | |
BR9811569A (pt) | Compostos que inibem a adesão de leucócito mediada por vla-4 | |
BR0007663A (pt) | Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4 | |
BR9811599A (pt) | Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4 | |
BR9812111A (pt) | Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4 | |
BR9811594A (pt) | Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4 | |
BR9811573A (pt) | Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4 | |
IL164225A0 (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by 4 integrins | |
BRPI0513143A (pt) | antagonistas de vla-4 multivalentes compreendendo porções poliméricas | |
EA200401561A1 (ru) | Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов | |
ZA200803016B (en) | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 | |
WO2000043354A3 (en) | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 | |
AU3246600A (en) | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists | |
AR029611A1 (es) | Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4 | |
AR022405A1 (es) | Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos | |
IL117295A (en) | 4-Aminotetrahydro-benzisoxazole or-isothiazole compounds and pharmaceutical compositions comprising them | |
AR026105A1 (es) | Compuetos heteroarilo, heterociclico y ilo que | |
AR042047A1 (es) | Compuestos de heteroarilo que inhiben la adhesion de leucocitos mediada por integrinas alfa 4 | |
AR042048A1 (es) | Compuestos heterociclicos que inhiben la adhesion de leucocitos mediada por integrinas alfa 4 | |
ECSP982560A (es) | 4,5 diarilimidazoles 2- sustituidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |